Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy
GSK Investigational Site, Malmö, Sweden
GSK Investigational Site, London, United Kingdom
AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece
Foundation Research, St. Petersburg, Florida, United States
GSK Investigational Site
Sunbelt Research Group, Llc, Mobile, Alabama, United States
Loma Linda Va Healthcare Systems, Loma Linda, California, United States
Mouhaffel, Assad H., West Monroe, Louisiana, United States
Centre d'Investigation Clinique, Montpellier, France
Pfizer Investigational Site, Jerusalem, Israel
GSK Investigational Site, Wigan, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.